Related Experiment Video

Updated: Jul 17, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Acquired apolipoprotein B deficiency with chronic hepatitis C virus infection

P Gupte1, A Dudhade, H G Desai

  • 1Department of Gastroenterology, Jaslok Hospital and Research Center, Mumbai 400 026, India.

Indian Journal of Gastroenterology : Official Journal of the Indian Society of Gastroenterology
|February 1, 2007
PubMed

Insights

Hepatitis C virus (HCV) infection can cause fatty liver and acquired Apolipoprotein B (ApoB) deficiency. Treating HCV improved lipid profiles and ApoB levels in patients with this condition.

Area of Science:

  • Hepatology
  • Lipid Metabolism
  • Virology

Background:

  • Chronic hepatitis C virus (HCV) infection is frequently linked to hepatic steatosis (fatty liver).
  • Apolipoprotein B (ApoB) deficiency is an established cause of fatty liver disease.
  • Acquired ApoB deficiency has been recently associated with HCV infection.

Observation:

  • Two patients presented with asymptomatic transaminase elevation, fatty liver, and high HCV viral load (genotype 3).
  • Both patients exhibited abnormal lipid profiles, including low total cholesterol, low-density lipoprotein (LDL), triglycerides, and ApoB levels.

Findings:

  • The study observed a correlation between HCV infection and acquired ApoB deficiency in the presented cases.
  • Treatment of HCV infection in one patient led to improvements in their lipid profile and ApoB levels.

Implications:

  • This case series suggests a potential link between HCV infection, particularly genotype 3, and acquired ApoB deficiency.
  • Effective HCV treatment may reverse or improve lipid abnormalities and ApoB deficiency associated with the infection.
  • Further research is warranted to elucidate the mechanisms underlying HCV-associated ApoB deficiency and its clinical significance.

More Related Videos

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...